• PN: A111405

COMPONENTS

45x Ab-conjugated beads (S5P10 - human IL-20 Ab-bead). PN: B111405A. One vial containing 100 µL of anti-human IL-20 conjugated to AimPlex Bead S5P10.

25x Biotin-detection Ab (human IL-20 Biotin-dAb). PN: B111405B. One vial containing 100 µL of biotinylated anti-human IL-20.

Lyophilized Standard Mix-Human Group 2 Panel B, 10-Plex. PN: HG20010. One vial containing lyophilized recombinant human IL-17F, IL-20, IL-21, IL-28A, IL-29, IL-33, M-CSF, MPO, TSLP, and VEGF-A. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human IL-20/IL-10D.  Can be multiplexed with other analytes in Human Group 2.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 2: Negligible

Sample volume: 15 µL/test

Description:

Interleukin 20 is a cytokine structurally related to interleukin 10 (IL-10). This cytokine has been shown to transduce its signal through signal transducer and activator of transcription 3 (STAT3) in keratinocytes. A specific receptor for this cytokine is found to be expressed in skin and upregulated dramatically in psoriatic skin, suggesting a role for this protein in epidermal function and psoriasis. In addition, IL-20 also causes cell expansion of multi-potential hematopoietic progenitor cells. Anti-IL-20 monoclonal antibodies have been researched as clinical candidates for the treatment or prevention of psoriasis, rheumatoid arthritis, atherosclerosis, osteoporosis, and stroke.

References:

1.      Rich BE, Kupper TS (August 2006). "Interleukin 20". Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 5 (3): 243–250. doi:10.2174/187152306778017683.

2.      Kragstrup TW, Otkjaer K, Holm C, Jørgensen A, Hokland M, Iversen L, Deleuran B (Jan 2008). "The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy". Cytokine 41 (1): 16–23. doi:10.1016/j.cyto.2007.10.004. PMID 18061474.

3.      Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS (Aug 2011). "Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss". The Journal of Experimental Medicine 208 (9): 1849–61. doi:10.1084/jem.20102234. PMID 21844205.